Figure 3.

Caraphenol A treatment during CD34⁺ cell LV transduction does not affect patterns of LV integration observed in human cells relative to DMSO-treated controls. A composite of individual integration events obtained from bone marrow and spleen samples (n = 8 mice per treatment and 2 MOIs, 32 mice total; see Figure 2A, at the terminal end point). (A) Frequency of unique integration events occurring relative to indicated genomic features, or within 30 kb of known oncogenes as a function of caraphenol A (green bars) or DMSO treatment (blue bars). (B) Probability density function for integration to occur within 100 kb of transcription start sites (Tss) for caraphenol A-treated (green dashed line) compared with DMSO-treated (blue solid line) bone marrow and spleen cells.